Payment overview · 2025
General Payments
$14.66
1 reported records · 1 companies
Healthcare provider profile · identity verified
Randy Eugene Oliver, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · METROPOLIS, IL · NPI 1245219443
Verified facts
What the public records show
CMS Open Payments records show Randy Eugene Oliver, M.D. received $14.66 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.66 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
241 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 164 |
| Potassium Chloride | Potassium Chloride | 553 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 527 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 79 |
| Losartan Potassium | Losartan Potassium | 474 | 102 |
| Omeprazole | Omeprazole | 424 | 69 |
| Lisinopril | Lisinopril | 401 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 345 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 80 |
| Furosemide | Furosemide | 330 | 63 |
| Gabapentin | Gabapentin | 289 | 62 |
| Allopurinol | Allopurinol | 265 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 264 | 59 |
| Eliquis | Apixaban | 241 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 65 |
| Montelukast Sodium | Montelukast Sodium | 226 | 43 |
| Jardiance | Empagliflozin | 217 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 40 |
| Metformin Hcl | Metformin Hcl | 211 | 43 |
| Metformin Hcl Er | Metformin Hcl | 205 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 172 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 23 |
| Memantine Hcl | Memantine Hcl | 171 | 16 |
| Carvedilol | Carvedilol | 146 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 53 |
| Mirtazapine | Mirtazapine | 129 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 33 |
| Bupropion Xl | Bupropion Hcl | 104 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 17 |
| Buspirone Hcl | Buspirone Hcl | 94 | 14 |
| Alprazolam | Alprazolam | 92 | 36 |
| Xarelto | Rivaroxaban | 88 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 13 |
| Spironolactone | Spironolactone | 81 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 29 |
| Famotidine | Famotidine | 78 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 15 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Lorazepam | Lorazepam | 71 | 15 |
| Simvastatin | Simvastatin | 71 | 18 |
| Enalapril Maleate | Enalapril Maleate | 70 | 20 |
| Ozempic | Semaglutide | 68 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 12 |
| Tradjenta | Linagliptin | 64 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 61 | 11 |
| Glimepiride | Glimepiride | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 13 |
| Meloxicam | Meloxicam | 59 | 23 |
| Trulicity | Dulaglutide | 59 | 16 |
| Glyburide | Glyburide | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 56 | 11 |
| Glipizide | Glipizide | 55 | 13 |
| Prednisone | Prednisone | 53 | 38 |
| Irbesartan | Irbesartan | 50 | 12 |
| Trazodone Hcl | Trazodone Hcl | 49 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 12 |
| Amantadine | Amantadine Hcl | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Primidone | Primidone | 48 | 11 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 11 |
| Tramadol Hcl | Tramadol Hcl | 41 | 15 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Bumetanide | Bumetanide | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Captopril | Captopril | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Cephalexin | Cephalexin | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.66 · 1 records | PFIZER INC. | ABRYSVO, COMIRNATY, PREVNAR 20 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error